Please login to the form below

Not currently logged in
Email:
Password:

GSK earns expanded approval for Volibris in Europe

Additional indication given to pulmonary arterial hypertension drug
GSK

GlaxoSmithKline's pulmonary arterial hypertension drug Volibris has won expanded approval from the European Commission. 

But, the decision is based on data from the phase III/IV AMBITION study, which showed that the combination of Volibris (ambrisentan) and tadalafil reduced the risk of clinical failure by 50% in treatment-naïve PAH patients compared to pooled ambrisentan and tadalafil monotherapy.

Jonathan Langley, clinical investigation lead for PAH at GSK, said: “PAH is a rare, chronic and life-changing disease that can result in heart failure and death if left untreated.

“The AMBITION study has demonstrated that the early combination of two treatments that target different pathways in PAH can halve the risk of clinical failure and more than half the rate of hospitalisation for patients, compared to either treatment given individually.

“The expanded authorisation for Volibris will make an important difference to the future management of PAH and the outcomes of patients living with this highly debilitating condition.”

The expanded approval will come as good news for GSK, which is facing competition from other PAH drugs such as Actelion's Opsumit (macitentan) and Uptravi (selexipag) as well as Bayer's Adempas (riociguat) and United Therapeutics' Orenitram (trepostinil).

Analysts have predicted that the PAH market will grow at around 2.3% a year to 2020 with revenues growing from just over $4bn in 2013 to $5.2bn in 2020.

Article by
Nikhil Patel

26th November 2015

From: Regulatory

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

#DemandDiversity: For International Women's Day, we ask... why do women often suffer from more side effects than men?
Women are largely prescribed exactly the same treatment regimens as men, with no account for the underlying differences in physiology and drug metabolism between the sexes....
Good design saves lives
Good design and creative thinking are essential if we are to improve on existing problems in new ways, which is why design and creativity within healthcare is vital. Health is...
Why you must understand the pricing of patient recruitment companies
Recruiting a diverse range of patients and engaging with them for your clinical trial isn’t an easy task, which means you might turn to patient recruitment companies, like us, who...

Infographics